Immune-Mediated Inflammatory Diseases: Addressing Safety Concerns and Enhancing the Accessibility of Biosimilars
Cláudia P Feiteira, Isabel C Tavares, Maria H L Ribeiro · 2026
Read Immune-Mediated Inflammatory Diseases: Addressing Safety Concerns and Enhancing the Accessibility of Biosimilars by Cláudia P Feiteira, Isabel C Tavares, Maria H L Ribeiro (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13503507.txt.
Description
Feiteira, Tavares, and Ribeiro review the stubborn gap between what biosimilar medicines can do and how little they are used. Biosimilars are near-copies of expensive biologic drugs for immune diseases such as psoriasis, lupus, and inflammatory bowel disease, and regulators approve them only after proving close similarity. Their 2026 review assembles trial and real-world switching evidence. It then asks why patients and doctors still hesitate, pointing at three brakes: doubts about swapping and extrapolation, poor communication, and the nocebo effect, where negative expectations themselves cause symptoms.
The evidence they summarise is reassuring across the board: no study found switching, even repeatedly or in reverse, raised immune reactions, lost effectiveness, or created new safety problems in these diseases. Success in practice, they argue, hinges on managing expectations as carefully as the pharmacology, with honest conversations before any switch.
Catalog record
| CREATOR | Cláudia P Feiteira, Isabel C Tavares, Maria H L Ribeiro |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 69 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |